{"id":"symbicort-turbuhaler","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Oral thrush"},{"rate":"10-20%","effect":"Headache"},{"rate":"10-20%","effect":"Cough"},{"rate":"5-10%","effect":"Pharyngitis"},{"rate":"5-10%","effect":"Dysphonia"}]},"_chembl":{"chemblId":"CHEMBL1370","moleculeType":"Small molecule","molecularWeight":"430.54"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Budesonide works by reducing inflammation in the lungs, while formoterol helps to relax the airway muscles, making it easier to breathe. This combination allows for improved control of symptoms and reduced risk of exacerbations.","oneSentence":"Symbicort Turbuhaler is a combination of budesonide, an inhaled corticosteroid, and formoterol, a long-acting beta2-adrenergic receptor agonist, used to control symptoms of asthma and chronic obstructive pulmonary disease (COPD).","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:36:58.482Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Maintenance and control of asthma symptoms"},{"name":"Maintenance and control of symptoms in COPD"}]},"trialDetails":[{"nctId":"NCT07426458","phase":"PHASE4","title":"Ventilation and Perfusion in Asthmatics","status":"NOT_YET_RECRUITING","sponsor":"University of Miami","startDate":"2026-04","conditions":"Asthma","enrollment":40},{"nctId":"NCT07433569","phase":"PHASE1","title":"A Study to Investigate How Budesonide and Formoterol Move Through the Body (Pharmacokinetics) When Delivered With Different Devices in Participants Aged 4 to Less Than 12 Years Old With Asthma","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2026-03-05","conditions":"Asthma","enrollment":12},{"nctId":"NCT06473779","phase":"PHASE3","title":"Open-label Study to Assess Reduction of Background Asthma Medication While Sustaining Asthma Control and Clinical Remission With Tezepelumab in Patients 12-80yrs With Severe Asthma.","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2024-09-30","conditions":"Severe Asthma","enrollment":326},{"nctId":"NCT05202262","phase":"PHASE3","title":"A 24-Week Efficacy and Safety Study to Assess Budesonide and Formoterol Fumarate Metered Dose Inhaler in Adult and Adolescent Participants With Inadequately Controlled Asthma (VATHOS)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2022-01-12","conditions":"Asthma","enrollment":645},{"nctId":"NCT06429475","phase":"PHASE3","title":"Anti-Inflammatory Reliever South Africa","status":"RECRUITING","sponsor":"University of KwaZulu","startDate":"2024-06-06","conditions":"Asthma","enrollment":1038},{"nctId":"NCT05689983","phase":"PHASE1, PHASE2","title":"Symptom-driven ICS/LABA Therapy for Adolescent Patients With Asthma Non-adherent to Daily Maintenance Inhalers","status":"ACTIVE_NOT_RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2022-04-01","conditions":"Asthma in Children, Nonadherence, Medication","enrollment":40},{"nctId":"NCT04609878","phase":"PHASE3","title":"Study to Assess PT010 in Adult and Adolescent Participants With Inadequately Controlled Asthma (KALOS)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2020-12-15","conditions":"Asthma","enrollment":2274},{"nctId":"NCT06272370","phase":"PHASE4","title":"Individualizing Treatment for Asthma in Primary Care","status":"COMPLETED","sponsor":"DARTNet Institute","startDate":"2024-02-01","conditions":"Asthma, Bronchial Diseases, Respiratory Tract Infections","enrollment":103},{"nctId":"NCT04609904","phase":"PHASE3","title":"Study to Assess PT010 in Adult and Adolescent Participants With Inadequately Controlled Asthma (LOGOS)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2021-03-01","conditions":"Asthma","enrollment":2187},{"nctId":"NCT03924635","phase":"PHASE4","title":"An Exploratory Study to Characterise Changes in Airway Inflammation, Symptoms, Lung Function and Reliever Use in Adult Asthma Patients","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2019-08-01","conditions":"Airway Inflammation, Asthma","enrollment":42},{"nctId":"NCT04159519","phase":"PHASE4","title":"A Study to Assess the Reduction of Daily Maintenance ICS/LABA Treatment Towards Anti-Inflammatory Reliever Treatment in Patients With Severe Eosinophilic Asthma Treated With Benralizumab","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2020-07-27","conditions":"Asthma, Severe Eosinophilic Asthma","enrollment":170},{"nctId":"NCT03888131","phase":"PHASE3","title":"Foster® pMDI (CHF 1535) Versus Symbicort® Turbohaler in COPD Patient","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2018-07-30","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":750},{"nctId":"NCT06568445","phase":"PHASE4","title":"Maintenance at Initial Treatment With Sequential Anti-Inflammation Reliever Therapy","status":"NOT_YET_RECRUITING","sponsor":"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine","startDate":"2024-08-12","conditions":"Bronchial Asthma","enrollment":90},{"nctId":"NCT06105671","phase":"NA","title":"U-LABA/ICS Effects on Exercise Performance, Formoterol","status":"COMPLETED","sponsor":"Morten Hostrup, PhD","startDate":"2024-01-05","conditions":"Exercise Performance","enrollment":20},{"nctId":"NCT02062463","phase":"PHASE3","title":"Study to Evaluate the Mastery of Inhaler Technique for Budesonide Formoterol (BF) SPIROMAX® as Compared to SYMBICORT® TURBOHALER® as Treatment for Adult Participants With Asthma","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2014-05-28","conditions":"Asthma","enrollment":485},{"nctId":"NCT01803555","phase":"PHASE3","title":"Efficacy and Safety Evaluation of Budesonide/Formoterol SPIROMAX® Inhalation Powder Versus SYMBICORT® TURBOHALER®","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2013-07-04","conditions":"Asthma","enrollment":605},{"nctId":"NCT00576069","phase":"","title":"Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma","status":"RECRUITING","sponsor":"Gelb, Arthur F., M.D.","startDate":"2007-10-25","conditions":"Asthma","enrollment":60},{"nctId":"NCT01225913","phase":"PHASE4","title":"Mechanism(s) of Airflow Limitation During Exacerbation of Asthma","status":"RECRUITING","sponsor":"Gelb, Arthur F., M.D.","startDate":"2007-10","conditions":"Asthma","enrollment":50},{"nctId":"NCT05322707","phase":"PHASE3","title":"BE Study Budesonide 80 μg and Formoterol Fumarate Dihydrate 4.5 μg Inhalation Product in Asthma Patient","status":"COMPLETED","sponsor":"Cipla Ltd.","startDate":"2022-04-15","conditions":"Asthma","enrollment":1485},{"nctId":"NCT04705727","phase":"PHASE3","title":"Budesonide/Formoterol Turbuhaler® Versus Terbutaline Nebulization as Reliever Therapy in Children With Moderate Asthma Exacerbation","status":"TERMINATED","sponsor":"Centre Hospitalier Intercommunal Creteil","startDate":"2021-08-23","conditions":"Asthma in Children","enrollment":102},{"nctId":"NCT03015259","phase":"PHASE3","title":"Randomized, Placebo-controlled, Multi-dose, Study Comparing Budesonide/Formoterol to Symbicort® in Asthmatic Patients","status":"COMPLETED","sponsor":"Kindeva Drug Delivery","startDate":"2016-12-29","conditions":"Asthma","enrollment":1762},{"nctId":"NCT03691961","phase":"NA","title":"Corticosteroids/β2-agonists in Hair in Asthmatic Patients (CorticHair)","status":"UNKNOWN","sponsor":"Hopital Foch","startDate":"2018-09-20","conditions":"Asthma","enrollment":24},{"nctId":"NCT04215848","phase":"PHASE3","title":"As-needed Budesonide/Formoterol Turbuhaler in Stepping Down Period","status":"COMPLETED","sponsor":"Hat Yai Medical Education Center","startDate":"2020-04-01","conditions":"Asthma","enrollment":31},{"nctId":"NCT02573233","phase":"PHASE2","title":"Evaluation of Dupilumab's Effects on Airway Inflammation in Patients With Asthma","status":"COMPLETED","sponsor":"Sanofi","startDate":"2016-01-27","conditions":"Asthma","enrollment":42},{"nctId":"NCT04078126","phase":"PHASE3","title":"Study Comparing Dual Combination of Product (Budesonide and Formoterol) Given Via Two Different Inhalers. To See Which One Results in the Best Effect on Breathing.","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2019-09-10","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":35},{"nctId":"NCT02237508","phase":"PHASE1","title":"A Clinical Study to Evaluate Z7200 (Budesonide/Formoterol) Pharmacokinetics Profile in Healthy Volunteers","status":"COMPLETED","sponsor":"Zambon SpA","startDate":"2014-09","conditions":"Asthma","enrollment":90},{"nctId":"NCT02631941","phase":"PHASE1","title":"Clinical Study to Evaluate Z7200 Pharmacokinetics Profile","status":"COMPLETED","sponsor":"Zambon SpA","startDate":"2016-01","conditions":"Asthma","enrollment":91},{"nctId":"NCT02227394","phase":"PHASE2","title":"Study to Compare the Effects of Z7200 And Symbicort® Turbohaler on Respiratory Imaging Parameters in Asthmatic Patients","status":"COMPLETED","sponsor":"Zambon SpA","startDate":"2014-08","conditions":"Asthma, Asthma Chronic, Asthma Bronchial","enrollment":20},{"nctId":"NCT01432080","phase":"PHASE2","title":"Steroids, Azithromycin, Montelukast, and Symbicort (SAMS) for Viral Respiratory Tract Infection Post Allotransplant","status":"TERMINATED","sponsor":"Maisonneuve-Rosemont Hospital","startDate":"2011-09","conditions":"Respiratory Tract Infections, Bronchiolitis Obliterans, Cryptogenic Organizing Pneumonia","enrollment":12},{"nctId":"NCT03468790","phase":"PHASE3","title":"Anti-IgE Monoclonal Antibody Treatment in Patients With Allergic Asthma.","status":"COMPLETED","sponsor":"Shanghai Biomabs Pharmaceutical Co., Ltd.","startDate":"2018-05-09","conditions":"Asthma, Allergic","enrollment":393},{"nctId":"NCT04331054","phase":"PHASE3","title":"Protective Role of Inhaled Steroids for Covid-19 Infection","status":"TERMINATED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2020-04-13","conditions":"Covid-19 Infection, Hospitalization in Respiratory Disease Department","enrollment":146},{"nctId":"NCT01070888","phase":"PHASE4","title":"Trial on the Effect of Budesonide/Formoterol and Inhaled Budesonide Alone on Exercise-Induced Asthma","status":"TERMINATED","sponsor":"Boston Children's Hospital","startDate":"2010-02","conditions":"Exercise Induced Asthma","enrollment":6},{"nctId":"NCT03197818","phase":"PHASE3","title":"Active Controlled Trial of CHF5993 Pressurized Metered-dose Inhaler ( pMDI) vs Symbicort®Turbuhaler® in Patients With Chronic Obstructive Pulmonary Disease ( COPD)","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2016-12-14","conditions":"COPD (Chronic Obstructive Pulmonary Disease)","enrollment":990},{"nctId":"NCT01117116","phase":"NA","title":"Sub-Sensitivity to Long-Acting Bronchodilators (LABA)","status":"COMPLETED","sponsor":"National Jewish Health","startDate":"2010-03","conditions":"Asthma","enrollment":21},{"nctId":"NCT01253473","phase":"PHASE4","title":"Symbicort in Airway Predominant Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"National Jewish Health","startDate":"2012-04","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":46},{"nctId":"NCT02497001","phase":"PHASE3","title":"A Randomized, Double-Blind, Parallel-Group, 24-Week, Chronic-Dosing, Multi-Center Study to Assess the Efficacy and Safety of PT010, PT003, and PT009 Compared With Symbicort® Turbuhaler® (Kronos)","status":"COMPLETED","sponsor":"Pearl Therapeutics, Inc.","startDate":"2015-08-10","conditions":"COPD","enrollment":1902},{"nctId":"NCT01787097","phase":"PHASE4","title":"Effect of Symbicort ® on GR in Sputum in COPD","status":"COMPLETED","sponsor":"Imperial College London","startDate":"2013-01","conditions":"Chronic Obstructive Lung Disease","enrollment":31},{"nctId":"NCT04607629","phase":"PHASE3","title":"An Efficacy and Safety Study of Genolar® and Xolar® in the Persistent Atopic Bronchial Asthma","status":"COMPLETED","sponsor":"AO GENERIUM","startDate":"2018-06-20","conditions":"Bronchial Asthma","enrollment":192},{"nctId":"NCT03114969","phase":"","title":"Comparative Study of Error Rates Between ELLIPTA® Dry Powder Inhaler (DPI) and Other DPIs","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2017-06-08","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":450},{"nctId":"NCT00915538","phase":"PHASE4","title":"Comparing Bronchodilation of Symbicort With and Without Valved Holding Chamber (Aerochamber Plus)","status":"COMPLETED","sponsor":"Western Sky Medical Research","startDate":"2009-07","conditions":"Asthma","enrollment":16},{"nctId":"NCT00413387","phase":"PHASE3","title":"Efficacy and Tolerability of Beclomethasone Dipropionate 100 µg + Formoterol 6 µg pMDI Via HFA-134a Vs. Budesonide 160 µg + Formoterol 4,5 µg Dry Powder Via Turbuhaler®. (Symbicort®)","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2004-09","conditions":"Bronchial Asthma","enrollment":219},{"nctId":"NCT04494321","phase":"PHASE1","title":"A Bioequivalence Pivotal Study of SYN010 HFA Inhaler and Symbicort® 160/4.5 in Healthy Volunteers Without Charcoal Block","status":"COMPLETED","sponsor":"Intech Biopharm Ltd.","startDate":"2017-06-19","conditions":"Asthma, COPD","enrollment":99},{"nctId":"NCT02972476","phase":"PHASE4","title":"Microbiome Use to Stratify Use of Inhaled Corticosteroids: MUSIC Trial","status":"COMPLETED","sponsor":"University of Dundee","startDate":"2016-12","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":158},{"nctId":"NCT03788395","phase":"PHASE4","title":"The Use of an Innovative Device for Therapeutic Adherence in Pediatric Asthma","status":"COMPLETED","sponsor":"Istituto per la Ricerca e l'Innovazione Biomedica","startDate":"2019-01-10","conditions":"Asthma","enrollment":18},{"nctId":"NCT03262012","phase":"PHASE3","title":"Study to Assess the Safety and Efficacy of PT010, PT003, and PT009 in Japanese Subjects With COPD Compared With Symbicort® Turbohaler®","status":"COMPLETED","sponsor":"Pearl Therapeutics, Inc.","startDate":"2016-08-09","conditions":"COPD","enrollment":416},{"nctId":"NCT02833480","phase":"PHASE2","title":"A Study to Investigate the Differential Effects of Inhaled Symbicort and Advair on Lung Microbiota","status":"UNKNOWN","sponsor":"University of British Columbia","startDate":"2015-02","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":69},{"nctId":"NCT00505388","phase":"","title":"A Follow-up Programme for Patients Using Symbicort SMART in Normal Clinical Practice","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2007-07","conditions":"Bronchial Asthma","enrollment":5137},{"nctId":"NCT02495168","phase":"PHASE3","title":"Randomized, Placebo-Controlled, Multidose, Study Comparing Generic Budesonide/Formoterol Fumarate Dihydrate to Symbicort® in Asthmatic Participants","status":"COMPLETED","sponsor":"Actavis Inc.","startDate":"2017-01-13","conditions":"Asthma","enrollment":1714},{"nctId":"NCT02224157","phase":"PHASE3","title":"A Clinical Study to Evaluate Symbicort Turbuhaler Used 'as Needed' in Adults and Adolescents With Asthma","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2014-11-28","conditions":"Asthma","enrollment":4215},{"nctId":"NCT02149199","phase":"PHASE3","title":"A Clinical Study to Evaluate Symbicort Turbuhaler Used 'as Needed' in Adults and Adolescents With Asthma.","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2014-07-07","conditions":"Asthma","enrollment":3850},{"nctId":"NCT00159263","phase":"NA","title":"Effect of Symbicort on GR Localisation in Asthma","status":"COMPLETED","sponsor":"Imperial College London","startDate":"2004-11","conditions":"Asthma","enrollment":10},{"nctId":"NCT02766608","phase":"PHASE3","title":"Study to Assess Efficacy and Safety of PT009 Compared to PT005, PT008, and Symbicort® Turbuhaler® on Lung Function Over 24-Weeks in Subjects With Moderate to Very Severe COPD","status":"COMPLETED","sponsor":"Pearl Therapeutics, Inc.","startDate":"2016-05-31","conditions":"Chronic Obstructive Pulmonary Disorder","enrollment":2389},{"nctId":"NCT00291408","phase":"PHASE4","title":"Effect of Symbicort on HAT and HDAC in Sputum Macrophages of COPD","status":"WITHDRAWN","sponsor":"Imperial College London","startDate":"2006-04","conditions":"Chronic Obstructive Pulmonary Disease (COPD), Age Matched Healthy Volunteers (Non-smokers)","enrollment":""},{"nctId":"NCT02546297","phase":"PHASE4","title":"Comparisons of Inhaled LAMA or LAMA+LABA or ICS+LABA for COPD With Bronchiectasis","status":"UNKNOWN","sponsor":"Shanghai Pulmonary Hospital, Shanghai, China","startDate":"2017-09-15","conditions":"COPD, Bronchiectasis","enrollment":90},{"nctId":"NCT01415518","phase":"PHASE4","title":"Efficacy and Tolerability Study in Severe Chronic Obstructive Pulmonary Disease (COPD) Patients","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2011-09-01","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":581},{"nctId":"NCT00996697","phase":"PHASE4","title":"Differential Trough Effects of 'Triple Therapy' on Pulmonary Function in Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Brian J Lipworth","startDate":"2006-10","conditions":"COPD","enrollment":23},{"nctId":"NCT02864342","phase":"PHASE4","title":"Adherence Study in COPD Patients","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2016-08-12","conditions":"Chronic Obstructive Pulmonary Disease (COPD","enrollment":138},{"nctId":"NCT01099722","phase":"PHASE3","title":"Assessment of the Efficacy and Safety of FlutiForm® pMDI 125/5 µg (2 Puffs Bid) Versus Symbicort® Turbohaler® 200/6 µg (2 Puffs Bid) in Adolescent and Adult Subjects With Moderate to Severe Persistent, Reversible Asthma","status":"COMPLETED","sponsor":"Mundipharma Research Limited","startDate":"2010-04","conditions":"Asthma","enrollment":261},{"nctId":"NCT02934607","phase":"PHASE1","title":"A Study to Assess How Much Drug Reaches the Blood When Given From Symbicort pMDI With Spacer Compared to That of Symbicort pMDI Without Spacer in Healthy Volunteers","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2016-11-04","conditions":"Study is Being Conducted in Healthy Volunteers","enrollment":50},{"nctId":"NCT02533505","phase":"PHASE4","title":"Phase IV O2 Consumption Study in COPD Patients.","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2015-08-25","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":51},{"nctId":"NCT03563001","phase":"PHASE4","title":"Differences of Small Airways Function Between Chronic Obstructive Pulmonary Disease(COPD) and Asthma-copd Overlap(ACO)","status":"UNKNOWN","sponsor":"Zhujiang Hospital","startDate":"2018-06-20","conditions":"Pulmonary Disease, Chronic Obstructive, Asthma-Chronic Obstructive Pulmonary Disease Overlap Syndrome, Small Airway Disease","enrollment":80},{"nctId":"NCT03551197","phase":"PHASE4","title":"Change of Lung Function After Exercise in Patients With Chronic Obstructive Pulmonary Disease","status":"UNKNOWN","sponsor":"Zhujiang Hospital","startDate":"2018-06-13","conditions":"Pulmonary Disease, Chronic Obstructive, Exercise, Lung Function Decreased","enrollment":50},{"nctId":"NCT02189304","phase":"PHASE1","title":"Pharmacokinetics and Safety Study of PT010 in Healthy Subjects","status":"COMPLETED","sponsor":"Pearl Therapeutics, Inc.","startDate":"2014-06-01","conditions":"COPD","enrollment":59},{"nctId":"NCT01290874","phase":"PHASE3","title":"Blacks and Exacerbations on Long Acting Beta Agonists (LABA) vs. Tiotropium (BELT)","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2011-03-30","conditions":"Asthma","enrollment":1070},{"nctId":"NCT02757209","phase":"NA","title":"Comparative Study on Usability of Inhaler Devices in Adults With Asthma or COPD","status":"COMPLETED","sponsor":"Consorzio Futuro in Ricerca","startDate":"2016-04","conditions":"Asthma, COPD","enrollment":84},{"nctId":"NCT02157935","phase":"PHASE3","title":"Comparing the Efficacy of Symbicort® pMDI and Formoterol Turbuhaler in Reducing Exacerbations in Patients With Cronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2014-06-27","conditions":"COPD Patients","enrollment":2026},{"nctId":"NCT02233803","phase":"PHASE4","title":"A Non-inferiority Study to Evaluate Efficacy, Safety and Tolerability of NEUMOTEROL® 400 and SYMBICORT® Forte in Adults With Asthma","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-11-14","conditions":"Asthma","enrollment":239},{"nctId":"NCT01218399","phase":"NA","title":"Use of Symbicort or Pulmicort to Treat Viral-mediated Asthma Exacerbations","status":"COMPLETED","sponsor":"Stanford University","startDate":"2009-09","conditions":"Asthma","enrollment":10},{"nctId":"NCT02257372","phase":"PHASE4","title":"A Study to Evaluate the Effect of Umeclidinium (UMEC) as Combination Therapy in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-09-30","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":236},{"nctId":"NCT01760304","phase":"PHASE4","title":"Changes in Cardiac Function in COPD Patients After Administration of Budesonide/Formoterol (Symbicort®) Versus Placebo","status":"TERMINATED","sponsor":"Brigham and Women's Hospital","startDate":"2012-01","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":5},{"nctId":"NCT02725242","phase":"PHASE3","title":"Efficacy of Once-daily Budesonide/Formoterol Turbuhaler 4.5/160 µg in Step Down Asthma","status":"COMPLETED","sponsor":"Hat Yai Medical Education Center","startDate":"2016-03","conditions":"Asthma","enrollment":77},{"nctId":"NCT02091986","phase":"PHASE3","title":"A 12-Week Study in Asthmatic Children Ages 6 to <12 Years, Investigating the Efficacy and Safety of Symbicort pMDI 80/2.25 μg and Symbicort pMDI 80/4.5 μg, Compared With Budesonide pMDI 80 μg","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2014-04","conditions":"Asthma","enrollment":882},{"nctId":"NCT01351792","phase":"PHASE3","title":"A Study in Patients With Chronic Obstructive Pulmonary Disease (FAIR)","status":"TERMINATED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2011-09","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":113},{"nctId":"NCT03073057","phase":"PHASE1","title":"Pharmacokinetic Study to Compare Absorption of Budesonide/Formoterol Easyhaler and Symbicort Turbuhaler","status":"COMPLETED","sponsor":"Orion Corporation, Orion Pharma","startDate":"2016-01","conditions":"Asthma","enrollment":20},{"nctId":"NCT01444430","phase":"PHASE3","title":"A 6 Month Safety Study Comparing Symbicort With Inhaled Corticosteroid Only in Asthmatic Adults and Adolescents","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2011-12","conditions":"Asthma","enrollment":12460},{"nctId":"NCT01713075","phase":"","title":"Symbicort Turbuhaler 30/60 Special Clinical Experience Investigation for Long-term Use for Chronic Obstructive Pulmonary Disease (COPD) Patients","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2012-11","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":1183},{"nctId":"NCT02934945","phase":"PHASE4","title":"Treatment Efficacy of Budesonide/Formoterol in Cough Variant Asthma and Typical Asthma Patients","status":"UNKNOWN","sponsor":"Zhujiang Hospital","startDate":"2015-09","conditions":"Bronchial Asthma","enrollment":30},{"nctId":"NCT00479739","phase":"PHASE4","title":"CONCEPT: A 1-Year Comparison Of A Stable Dose Of SERETIDE® Inhaler With An Adjustable Maintenance Dose Of SYMBICORT® Inhaler. SERETIDE® Inhaler is a Trademark of GSK Group of Companies. SYMBICORT® Inhaler is a Trademark of Astra Zeneca.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2002-11","conditions":"Asthma","enrollment":700},{"nctId":"NCT01712854","phase":"PHASE4","title":"Effects of Symbicort on the Ventilatory Kinematics","status":"TERMINATED","sponsor":"Columbia University","startDate":"2012-03","conditions":"Chronic Obstructive Lung Disease","enrollment":9},{"nctId":"NCT01961154","phase":"NA","title":"Stepping Down of Asthma Medication in Controlled Asthma","status":"COMPLETED","sponsor":"Kuopio University Hospital","startDate":"2012-10","conditions":"Asthma","enrollment":56},{"nctId":"NCT02850484","phase":"PHASE1","title":"A Bioequivalence Pivotal Study of SYN010 HFA Inhaler and Symbicort® 160/4.5 in Healthy Volunteers With Charcoal Block","status":"COMPLETED","sponsor":"Intech Biopharm Ltd.","startDate":"2016-03","conditions":"Asthma, Chronic Obstructive Pulmonary Disease (COPD)","enrollment":99},{"nctId":"NCT01711840","phase":"","title":"Clinical Experience Investigation of Symbicort Turbuhaler as Maintenance Therapy and Reliever Therapy","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2012-11","conditions":"Bronchial Asthma","enrollment":2409},{"nctId":"NCT02570425","phase":"NA","title":"Comparing Maintenance of Device Mastery With Turbohaler© vs. Spiromax© in Healthcare Professionals naïve to Both Devices","status":"COMPLETED","sponsor":"Research in Real-Life Ltd","startDate":"2014-07","conditions":"Asthma","enrollment":516},{"nctId":"NCT01921127","phase":"","title":"Comparative Effectiveness of Symbicort vs. Advair Among COPD Patients","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2013-08","conditions":"COPD","enrollment":3000},{"nctId":"NCT01917643","phase":"","title":"Comparative Effectiveness of Symbicort vs. Spiriva Among COPD Patients","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2013-08","conditions":"COPD Exacerbation","enrollment":2396},{"nctId":"NCT00784953","phase":"","title":"Real Life Effectiveness in Patients With Not Optimally Controlled Asthma","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2008-10","conditions":"Asthma","enrollment":842},{"nctId":"NCT02574975","phase":"PHASE4","title":"Assessment of Airway Responsiveness and Treatment Efficacy in Asthmatics","status":"UNKNOWN","sponsor":"Zhujiang Hospital","startDate":"2015-04","conditions":"Asthma","enrollment":80},{"nctId":"NCT02308098","phase":"PHASE3","title":"To Confirm Equivalent Bronchodilator Efficacy of the Test Product Compared to the Reference Product","status":"COMPLETED","sponsor":"Orion Corporation, Orion Pharma","startDate":"2014-12","conditions":"Asthma","enrollment":72},{"nctId":"NCT01397890","phase":"PHASE4","title":"Efficacy and Tolerability of Symbicort as an add-on Treatment to Spiriva Compare With Spiriva Alone in Patients With Severe Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2011-07","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":793},{"nctId":"NCT01769898","phase":"PHASE4","title":"The Role of Theophylline Plus Low-dose Formoterol-budesonide in Treatment of Bronchiectasis","status":"COMPLETED","sponsor":"The First Affiliated Hospital of Guangzhou Medical University","startDate":"2013-07","conditions":"Bronchiectasis","enrollment":50},{"nctId":"NCT00858286","phase":"PHASE4","title":"A Follow-up Survey to Compare Stable Dosing (SERETIDE) With SYMBICORT, SMART, Maintenance and Reliever Therapy in One Inhaler in Moderate and Severe Asthmatics.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-02","conditions":"Asthma","enrollment":56},{"nctId":"NCT01404013","phase":"PHASE4","title":"Effects of Leukotriene Modulator Montelukast on Cough Variant Asthma","status":"UNKNOWN","sponsor":"The First Affiliated Hospital of Guangzhou Medical University","startDate":"2012-02","conditions":"Asthma","enrollment":99},{"nctId":"NCT01070784","phase":"PHASE3","title":"A Safety and Efficacy Study of Symbicort Turbuhaler Compared With Standard Chronic Obstructive Pulmonary Disease (COPD) Treatment in Japan","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2010-01","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":328},{"nctId":"NCT01980615","phase":"PHASE1","title":"Phase I Study Evaluating the Safety and Pharmacokinetics of Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol (BGF MDI) in Healthy Volunteers","status":"COMPLETED","sponsor":"Pearl Therapeutics, Inc.","startDate":"2013-11","conditions":"Healthy Volunteers","enrollment":84},{"nctId":"NCT02093195","phase":"PHASE2","title":"Study of Bosentan in the Treatment of Stable Severe Chronic Obstructive Pulmonary Disease Patients","status":"UNKNOWN","sponsor":"Air Force Military Medical University, China","startDate":"2013-12","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":40},{"nctId":"NCT01360021","phase":"PHASE3","title":"New Breath Actuated MDI Symbicort Compared to Symbicort pMDI and Budesonide pMDI for 12 Weeks Twice a Day","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2011-11","conditions":"Asthma","enrollment":214},{"nctId":"NCT01839851","phase":"","title":"Hair Cortisol in Asthma or Allergic Rhinitis Treated With Topical Corticosteroids","status":"UNKNOWN","sponsor":"Meir Medical Center","startDate":"2013-05","conditions":"ASTHMA, ALLERGIC RHINITIS","enrollment":60},{"nctId":"NCT01136655","phase":"PHASE2","title":"A Study in Asthmatic Children (6 to <12 Yrs) Comparing Single Doses of Formoterol and Foradil® Evaluating Efficacy","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2010-09","conditions":"Asthma","enrollment":54},{"nctId":"NCT01232335","phase":"","title":"Symbicort Turbuhaler 30/60 Specific Clinical Experience Investigation","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2010-01","conditions":"Bronchial Asthma","enrollment":1500},{"nctId":"NCT00624754","phase":"PHASE2","title":"Prospective Evaluation of the Efficacy of Budesonide/Formoterol in Bronchiolitis Obliterans in AHSCT","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2008-03","conditions":"Obstructive Airway Disease","enrollment":32}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":70,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Symbicort Turbuhaler 160/4.5 microg"],"phase":"phase_3","status":"active","brandName":"Symbicort Turbuhaler","genericName":"Symbicort Turbuhaler","companyName":"Orion Corporation, Orion Pharma","companyId":"orion-corporation-orion-pharma","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Symbicort Turbuhaler is a combination of budesonide, an inhaled corticosteroid, and formoterol, a long-acting beta2-adrenergic receptor agonist, used to control symptoms of asthma and chronic obstructive pulmonary disease (COPD). Used for Maintenance and control of asthma symptoms, Maintenance and control of symptoms in COPD.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}